Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TISA 818

Next Previous
Drug Profile

TISA 818

Alternative Names: TISA-818; UP-818-CC

Latest Information Update: 03 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EnliTISA (Shanghai) Pharmaceutical
  • Developer EnliTISA Shanghai Pharmaceutical
  • Class Anti-inflammatories; Antifibrotics
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adult respiratory distress syndrome
  • Phase I/II Stomatitis
  • Phase I Idiopathic pulmonary fibrosis

Most Recent Events

  • 03 Feb 2026 Jiangyin Berison Pharmaceutical/Shanghai Hequan Pharmaceutical completes a phase II trial in Adult respiratory distress syndrome in China (IV) (NCT07319351)
  • 04 Sep 2025 EnliTISA Shanghai Pharmaceutical plans to file a regulatory application in Chronic obstructive pulmonary disease for clinical trial approval (Enlitisa (Shanghai) Pharmaceutical pipeline, September 2025)
  • 05 Sep 2024 Preclinical trials in Stomatitis in China (Topical) before September 2024 ((Enlitisa (Shanghai) Pharmaceutical pipeline, September 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top